Deficiency of ATP6V1H causes bone loss by inhibiting bone resorption and bone formation through the TGF-β1 pathway

Theranostics

Volumn 6, Issue 12, 2016, Pages 2183-2195

  Duan, Xiaohong ^a   Liu, Jin ^a   Zheng, Xueni ^a   Wang, Zhe ^a   Zhang, Yanli ^a   Hao, Ying ^a   Yang, Tielin ^b   Deng, Hongwen ^c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c TULANE UNIVERSITY   (United States)

Author keywords

ATP6V1H; CRISPR Cas9; OPG; Osteoclasts; Osteoporosis; PH; RANKL; TGF 1; V ATPase

Indexed keywords

CRISPR ASSOCIATED PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; ATP6V1H PROTEIN, HUMAN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATP6V1H GENE; BONE DENSITY; BONE MATRIX; BONE MINERALIZATION; BONE REMODELING; CELL PH; CHINESE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; KNOCKOUT MOUSE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; BONE DEVELOPMENT; CHINA; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BONE RESORPTION; CHINA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE, KNOCKOUT; OSTEOGENESIS; OSTEOPOROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA1; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84995489181     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.17140     Document Type: Article

References (44)

1. Cipriano DJ, Wang Y, Bond S, Hinton A, Jefferies KC, Qi J, et al. Structure and regulation of the vacuolar ATPases. Biochim Biophys Acta. 2008; 1777: 599-604.
2. Yao G, Feng H, Cai Y, Qi W, Kong K. Characterization of vacuolar-ATPase and selective inhibition of vacuolar-H(+)-ATPase in osteoclasts. Biochem Biophys Res Commun. 2007; 357: 821-7.
3. Frattini A, Orchard PJ, Sobacchi C, Giliani S, Abinun M, Mattsson JP, et al. Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet. 2000; 25: 343-6.
4. Susani L, Pangrazio A, Sobacchi C, Taranta A, Mortier G, Savarirayan R, et al. TCIRG1-dependent recessive osteopetrosis: mutation analysis, functional identification of the splicing defects, and in vitro rescue by U1 snRNA. Hum Mutat. 2004; 24: 225-35.
5. Scimeca JC, Quincey D, Parrinello H, Romatet D, Grosgeorge J, Gaudray P, et al. Novel mutations in the TCIRG1 gene encoding the a3 subunit of the vacuolar proton pump in patients affected by infantile malignant osteopetrosis. Hum Mutat. 2003; 21: 151-7.
6. Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, Andolina M, et al. The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet. 2001; 10: 1767-73.
7. Li YP, Chen W, Liang Y, Li E, Stashenko P. Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet. 1999; 23: 447-51.
8. Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med. 2006; 12: 1403-9.
9. Kim T, Ha H, Kim N, Park ES, Rho J, Kim EC, et al. ATP6v0d2 deficiency increases bone mass, but does not influence ovariectomy-induced bone loss. Biochem Biophys Res Commun. 2010; 403: 73-8.
10. Wu H, Xu G, Li YP. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J Bone Miner Res. 2009; 24: 871-85.
11. Feng S, Deng L, Chen W, Shao J, Xu G, Li YP. Atp6v1c1 is an essential component of the osteoclast proton pump and in F-actin ring formation in osteoclasts. Biochem J. 2009; 417: 195-203.
12. Lee BS, Holliday LS, Krits I, Gluck SL. Vacuolar H+-ATPase activity and expression in mouse bone marrow cultures. J Bone Miner Res. 1999; 14: 2127-36.
13. Vitavska O, Wieczorek H, Merzendorfer H. A novel role for subunit C in mediating binding of the H+-V-ATPase to the actin cytoskeleton. J Biol Chem. 2003; 278: 18499-505.
14. Perez-Sayans M, Suarez-Penaranda JM, Barros-Angueira F, Diz PG, Gandara-Rey JM, Garcia-Garcia A. An update in the structure, function, and regulation of V-ATPases: the role of the C subunit. Braz J Biol. 2012; 72: 189-98.
15. Holliday LS, Lu M, Lee BS, Nelson RD, Solivan S, Zhang L, et al. The amino-terminal domain of the B subunit of vacuolar H+-ATPase contains a filamentous actin binding site. J Biol Chem. 2000; 275: 32331-7.
16. Chen SH, Bubb MR, Yarmola EG, Zuo J, Jiang J, Lee BS, et al. Vacuolar H+-ATPase binding to microfilaments: regulation in response to phosphatidylinositol 3-kinase activity and detailed characterization of the actin-binding site in subunit B. J Biol Chem. 2004; 279: 7988-98.
17. Yuan Y, Zhang J, Chang Q, Zeng J, Xin F, Wang J, et al. De novo mutation in ATP6V1B2 impairs lysosome acidification and causes dominant deafness-onychodystrophy syndrome. Cell Res. 2014; 24: 1370-3.
18. Kortum F, Caputo V, Bauer CK, Stella L, Ciolfi A, Alawi M, et al. Mutations in KCNH1 and ATP6V1B2 cause Zimmermann-Laband syndrome. Nat Genet. 2015; 47: 661-7.
19. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005; 115: 3318-25.
20. Peacock M, Turner CH, Econs MJ, Foroud T. Genetics of Osteoporosis. Endocrine Reviews. 2002; 23: 303-26.
21. Tan LJ, Wang ZE, Wu KH, Chen XD, Zhu H, Lu S, et al. Bivariate Genome-Wide Association Study Implicates ATP6V1G1 as a Novel Pleiotropic Locus Underlying Osteoporosis and Age at Menarche. The Journal of Clinical Endocrinology & Metabolism. 2015; 100: E1457-E66.
22. Yang TL, Guo Y, Liu YJ, Shen H, Liu YZ, Lei SF, et al. Genetic variants in the SOX6 gene are associated with bone mineral density in both Caucasian and Chinese populations. Osteoporos Int. 2012; 23: 781-7.
23. Yang TL, Guo Y, Li J, Zhang L, Shen H, Li SM, et al. Gene-gene interaction between RBMS3 and ZNF516 influences bone mineral density. J Bone Miner Res. 2013; 28: 828-37.
24. Pircher R, Jullien P, Lawrence DA. Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun. 1986; 136: 30-7.
25. Miyazono K, Hellman U, Wernstedt C, Heldin CH. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem. 1988; 263: 6407-15.
26. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, et al. TGF-[beta]1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009; 15: 757-65.
27. Zhen G, Wen C, Jia X, Li Y, Crane JL, Mears SC, et al. Inhibition of TGF-[beta] signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013; 19: 704-12.
28. Qin A, Cheng TS, Pavlos NJ, Lin Z, Dai KR, Zheng MH. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption. Int J Biochem Cell Biol. 2012; 44: 1422-35.
29. Vitavska O, Merzendorfer H, Wieczorek H. The V-ATPase subunit C binds to polymeric F-actin as well as to monomeric G-actin and induces cross-linking of actin filaments. J Biol Chem. 2005; 280: 1070-6.
30. Delany AM, Amling M, Priemel M, Howe C, Baron R, Canalis E. Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest. 2000; 105: 915-23.
31. Zhao H, Ito Y, Chappel J, Andrews NW, Teitelbaum SL, Ross FP. Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion. Dev Cell. 2008; 14: 914-25.
32. Qiu N, Xiao Z, Cao L, Buechel MM, David V, Roan E, et al. Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. J Cell Sci. 2012; 125: 1945-57.
33. Wang X, Zhen L, Miao H, Sun Q, Yang Y, Que B, et al. Concomitant Retrograde Coronary Venous Infusion of Basic Fibroblast Growth Factor Enhances Engraftment and Differentiation of Bone Marrow Mesenchymal Stem Cells for Cardiac Repair after Myocardial Infarction. Theranostics. 2015; 5: 995-1006.
34. Rahmi G, Pidial L, Silva AK, Blondiaux E, Meresse B, Gazeau F, et al. Designing 3D Mesenchymal Stem Cell Sheets Merging Magnetic and Fluorescent Features: When Cell Sheet Technology Meets Image-Guided Cell Therapy. Theranostics. 2016; 6: 739-51.
35. Karsdal MA, Hjorth P, Henriksen K, Kirkegaard T, Nielsen KL, Lou H, et al. Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem. 2003; 278: 44975-87.
36. Nishimura R. A novel role for TGF-[beta]1 in bone remodeling. IBMS BoneKEy. 2009; 6: 434-8.
37. Kasagi S, Chen W. TGF-beta1 on osteoimmunology and the bone component cells. Cell Biosci. 2013; 3: 4.
38. Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics. 2011; 1: 154-88.
39. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013; 339: 823-6.
40. Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28: 2-17.
41. Huss M, Ingenhorst G, Konig S, Gassel M, Drose S, Zeeck A, et al. Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c. J Biol Chem. 2002; 277: 40544-8.
42. Wieczorek H, Cioffi M, Klein U, Harvey WR, Schweikl H, Wolfersberger MG. Isolation of goblet cell apical membrane from tobacco hornworm midgut and purification of its vacuolar-type ATPase. Methods in Enzymology Biomembranes Part W: Cellular and Subcellular Transport: Epithelial Cells. 192 ed: Academic Press. 1990:608-16.
43. McCurley N, Mellman I. Monocyte-Derived Dendritic Cells Exhibit Increased Levels of Lysosomal Proteolysis as Compared to Other Human Dendritic Cell Populations. PLoS One. 2010; 5: e11949.
44. Yang T, Zhang Y, Li Y, Hao Y, Zhou M, Dong N, et al. High amounts of fluoride induce apoptosis/cell death in matured ameloblast-like LS8 cells by downregulating Bcl-2. Arch Oral Biol. 2013; 58: 1165-73.